Chardan Capital Rates Arrowhead Pharmaceuticals (ARWR) buy

Chardan Capital maintains its buy rating on Arrowhead Pharmaceuticals, targeting $90, a 10.42% upside from the current price.

By TradeTexts Research Desk · Published Jun 30, 2026, 9:03 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated Arrowhead Pharmaceuticals, Inc. ($ARWR) "buy" with a $90 price target on June 30, 2026.

Since the rating, $ARWR is up 6.7% after 1 week, up 7.1% after 1 month and down 31.4% to date (from the $81.51 close on Jun 30, 2026).

ARWR Arrowhead Pharmaceuticals, Inc.

$55.90 -17.54% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital reiterated its buy rating on Arrowhead Pharmaceuticals, setting a $90 price target.
Chardan Capital's $90 price target implies 10.42% upside from Arrowhead Pharmaceuticals, Inc.'s ($ARWR) current $81.51 share price.
Arrowhead Pharmaceuticals traded at approximately $80.5 on Tuesday, with a market cap of about $11.1 billion.
Insiders like COO Patrick O'Brien have been buying shares, while analysts maintain positive ratings.

Get $ARWR trade alerts by text

We text you when insiders, Congress or big funds trade $ARWR. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Arrowhead Pharmaceuticals, Inc. alert may contain errors. Disclosures

Chardan Capital has reaffirmed its positive outlook on Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR) by maintaining a buy rating and setting a price target of $90. This update came from analyst Keay Nakae on June 30, 2026. Shares of Arrowhead traded around $80.5 on Tuesday.

Arrowhead Pharmaceuticals, Inc. Stock Up 22.6%

Arrowhead Pharmaceuticals has a market capitalization of approximately $11.1 billion. The stock's forward P/E ratio is not meaningful as the company isn't profitable, with an EPS of -$2.27. The stock's beta is 1.275, indicating moderate volatility. Over the past year, shares have ranged from a low of $14.3 to a high of $84.55. The 50-day moving average is $75.48, while the 200-day moving average is $59.42. Arrowhead's current and quick ratios are strong at 6.23 and 6.09, respectively, though it has a high debt-to-equity ratio of 231.049.

12-month forecast

$ARWR price target

Arrowhead Pharmaceuticals, Inc. daily closes and this analyst's $90 target. Not advice.

Recent Earnings

Arrowhead Pharmaceuticals reported revenue of $622 million, but with a negative growth rate of 86.4%. The company also posted a net margin of -48.4% and a return on equity of -42.4%. The next earnings announcement is expected on August 6, 2026.

Insider Buying and Selling at Arrowhead Pharmaceuticals, Inc.

Recent insider activity includes significant transactions. On January 6, 2026, COO Patrick O'Brien purchased 75,000 shares. Meanwhile, Chief Medical Officer James Hamilton sold 10,000 shares on April 23, 2026, at $75.00 per share under a Rule 10b5-1 plan. CFO Daniel Joseph Apel also sold 13,095 shares on April 22, 2026, at an average price of $71.35, also under a planned sale.

Analysts Set New Price Targets

On June 30, 2026, Chardan Capital maintained its buy rating for Arrowhead Pharmaceuticals with a price target of $90. Other analysts have also weighed in: RBC Capital maintained a buy rating with an $87 target on May 8, 2026, and Morgan Stanley upgraded the stock to a buy with a $100 target on April 21, 2026. The consensus among analysts is a buy, with a mean target price of $89.08 based on 12 opinions.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biotechnology company headquartered in Pasadena, California. It focuses on developing medicines for treating complex diseases. The company's pipeline includes several RNA interference (RNAi) therapeutics in various stages of clinical trials, targeting conditions like cardiovascular and liver diseases. Arrowhead collaborates with major pharmaceutical firms such as GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Dr. Christopher R. Anzalone serves as the CEO, and the company employs around 711 people.

Bottom Line

Chardan Capital's reaffirmation of its buy rating for Arrowhead Pharmaceuticals highlights continued confidence in the company's prospects. Investors often track such analyst updates for insights into potential stock performance. Remember, these ratings are based on past data and may not reflect current market conditions.